1. Metabolic Enzyme/Protease
  2. Factor Xa

Factor Xa

Factor Xa is the activated form of the coagulation factor thrombokinase, known eponymously as Stuart-Prower factor. Factor X is an enzyme, a serine endopeptidase, which plays a key role at several stages of the coagulation system. Factor X is synthesized in the liver. Factor Xa has emerged as an attractive target for novel anticoagulants for its key position in the coagulation cascade and its limited roles outside of coagulation. The most commonly used anticoagulants in clinical practice, warfarin and the heparin series of anticoagulants and fondaparinux, act to inhibit the action of Factor Xa in various degrees. As a result, the past decade has witnessed an explosion of research into small-molecule, oral, direct Factor Xa inhibitors, and several are now in clinical development.

Factor Xa Related Products (14):

Cat. No. Product Name Effect Purity
  • HY-50903
    Rivaroxaban Inhibitor 99.96%
    Rivaroxaban is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
  • HY-50667
    Apixaban Inhibitor 99.97%
    Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
  • HY-10264B
    Edoxaban tosylate monohydrate Inhibitor 99.85%
    Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention
  • HY-B0597
    Fondaparinux sodium Inhibitor >98.0%
    Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.
  • HY-10268
    Betrixaban Inhibitor 98.85%
    Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with IC50 of 1.5 nM.
  • HY-12631
    BMS-654457 Inhibitor
    BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with Kis of 0.2 and 0.42 nM, respectively.
  • HY-76948
    5-R-Rivaroxaban Inhibitor 99.72%
    5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM).
  • HY-B0428A
    Ozagrel sodium Inhibitor 99.91%
    Ozagrel(OKY-046) sodium salt is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.
  • HY-70035
    Otamixaban Inhibitor
    Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.
  • HY-B0385
    Gabexate mesylate Inhibitor 98.51%
    Gabexate Mesylate is a Factor X inhibitor.
  • HY-B0428
    Ozagrel Inhibitor 99.96%
    Ozagrel(OKY-046) is an antiplatelet agent working as a thromboxane A2 synthesis inhibitor.
  • HY-19373
    RWJ-445167 Inhibitor
    RWJ-445167 is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
  • HY-10264A
    Edoxaban tosylate Inhibitor
    Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention IC50 Value: Target: factor Xa Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses[1].
  • HY-10264
    Edoxaban Inhibitor
    Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention